DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cholangiocarcinoma Treatment Landscape. Click here to read more @ Cholangiocarcinoma Pipeline Outlook
Key Takeaways from the Cholangiocarcinoma Pipeline Report
Discover groundbreaking developments in Cholangiocarcinoma Therapies! Gain in-depth knowledge of key Cholangiocarcinoma clinical trials, emerging drugs, and market opportunities @ Cholangiocarcinoma Clinical Trials Assessment
Cholangiocarcinoma Emerging Drugs Profile
Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. It is currently being evaluated in Phase III stage of development to treat biliary tract cancer.
Discovered in-house by Eisai’s Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, and FGFR3. Distinct from prior known FGFR inhibitors, E7090 has a basic structure that lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that E7090 demonstrates antitumor effects due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR1. A Phase II clinical trial of E7090 is underway to evaluate the efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion. E7090 received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan.
ABC294640 (Opaganib) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory, and antiviral activities. Opaganib inhibits SK2, a lipid kinase that catalyzes the formation of the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P promotes cancer growth, and proliferation and pathological inflammation, including TNFα signaling, and other inflammatory cytokine production. Specifically, by inhibiting the SK2 enzyme, opaganib blocks the synthesis of S1P, which regulates fundamental biological processes such as cell proliferation, migration, immune cell trafficking and angiogenesis, and is also involved in immune modulation and suppression of innate immune responses from T cells. Preliminary evidence suggests that because of its specificity for targeting SK2 rather than SK1, opaganib may have a better therapeutic ratio than nonspecific sphingosine kinase inhibitors or those targeting only SK1. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of cholangiocarcinoma.
TT-00420 is a highly innovative, clinical-stage, spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. A large number of preclinical studies have found that TT-00420 has a promising inhibitory effect on triple-negative breast cancer, cholangiocarcinoma, and other malignant tumors. TT-00420 was granted Orphan Drug Designation and fast track designation by the FDA and is currently in the Phase II stage of its development for the treatment of cholangiocarcinoma.
KIN-3248 is a small molecule kinase inhibitor that targets cancer associated alterations in the FGFR2 and FGFR3 genes. KIN-3248 aims to address the primary driver alteration and clinically observed and predicted FGFR2/3 mutations. The company is currently evaluating the safety and tolerability of KIN-3248 in the Phase I stage of its development for the treatment of cholangiocarcinoma.
The Cholangiocarcinoma Pipeline Report Provides Insights into
Stay informed about the Cholangiocarcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Cholangiocarcinoma Unmet Needs
Cholangiocarcinoma Companies
Merck Sharp & Dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio and others.
Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Cholangiocarcinoma Products have been categorized under various Molecule types such as
Transform your understanding of the Cholangiocarcinoma Pipeline! See the latest progress in drug development and clinical research @ Cholangiocarcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Cholangiocarcinoma Pipeline Report
Stay Ahead in Oncology Research–Access the Full Cholangiocarcinoma Pipeline Analysis Today! @ Cholangiocarcinoma Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-pipeline-insight
